LATEST FROM THE BLOG:
2020 is in the rearview mirror as the year no one was prepared for. During COVID, Prelude to a Cure (Prelude/P2AC) found itself at odds with our mission and goal with the need to be safe and socially distant from each other. Though, we were not idle. The Board of Prelude took a look at ourselves and realized we had room for improvement to redefine ourselves so that you know exactly who we are, what we do, how to get involved, give and see the research we’ve funded.
Prelude began 8 years ago with the determination to provide critical funding for the least funded of the major cancers; lung cancer. Our focus remains unique in that our purpose to provide “seed grants” for young investigators is more vital and in demand. These ideas at their emergent stage become the new ideas that can grow into world changing discoveries. For you; our family, friends, donors, supporters, patients/survivors and caregivers it means that together, we have work to do. Yes, we’re the elephant in the room, the one cancer that evokes many strong emotions and reactions which have become a part of our unconscious bias.Read more…
Our Twitter feed
We invite you to visit our Memorial Page where we honor our loved ones and friends—brave men and women who fought lung cancer with every ounce of their might. Their spirit drives our mission to keep fighting lung cancer and to fund innovative research: https://t.co/pspph6V9zc. https://t.co/Evq4TyELfq
A single-center, retrospective study reveals that approximately 11% of patients diagnosed with lung cancer concurrently have an abdominal aortic aneurysm (AAA). Researchers theorize dual screening could save lives. https://t.co/z05IfebR7l #lungcancer #Tampa #StPete
More than 135,000 Americans will die this year from lung cancer. The disease is also disproportionately funded relative to other more treatable diseases. Progress in finding a cure to this disease has been slow but is moving forward. (1/2) https://t.co/lohdjaTBIx